Patients receiving nipocalimab plus standard of care improved by 4.7 points on the MG-ADL score, significantly more than placebo, and that was from baseline over weeks 22, 23, and 24, so around 6 ...

Findings showed nipocalimab plus standard of care (SOC) improved MG-ADL score from baseline by 4.70 points compared with 3.25 points with placebo plus SOC over weeks 22, 23, and 24. The Food and ...

Nipocalimab demonstrates significant long-term efficacy and safety in generalized myasthenia gravis, improving MG-ADL scores and reducing immunoglobulin G levels. The phase 3 Vivacity-MG3 study ...

SAVANNAH, Ga. -- Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III ...

(RTTNews) - Johnson & Johnson (JNJ) a pharmaceutical, biotechnology, and medical technologies corporation, on Thursday announced positive results from the Phase 3 Vivacity-MG3 study of nipocalimab ...

Johnson & Johnson’s ‘Swiss army knife’ for autoimmune diseases – FcRn inhibitor nipocalimab – has shown efficacy in Sjogren’s disease (SjD), an autoimmune condition that affects ...

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad population of antibody ...

J ohnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for its drug nipocalimab in the treatment of antibody-positive patients ...